HIV Drug's weight gain mystery: healthy volunteer study probes root cause
NCT ID NCT04771754
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial studied 16 healthy volunteers to see if the HIV drug dolutegravir affects insulin sensitivity, fat metabolism, and hormone levels. Researchers aim to understand why some HIV patients gain weight while taking this medication. Participants took dolutegravir or a placebo, and changes were measured using advanced techniques like glucose clamps and calorimetry.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dolutegravir (Tivicay)
What this could lead to
If successful, this could help explain why some HIV patients gain weight on dolutegravir, potentially leading to better management strategies.
What could go wrong
This is a small, early-phase study in healthy volunteers, not HIV patients, so results may not directly apply to the real-world setting. It only looks at short-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION ON HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arnold Xhikola
London, SW10 0XD, United Kingdom